Allogeneic HCT for Hematologic Malignancies: Immune Manipulations
同种异体 HCT 治疗血液系统恶性肿瘤:免疫操作
基本信息
- 批准号:7585357
- 负责人:
- 金额:$ 24.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-02-01 至 2014-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Graft Versus Host DiseaseAcute Myelocytic LeukemiaAddressAdoptive ImmunotherapyAffectAgeAllogenicAllograftingAmbulatory CareAntitumor ResponseAreaBusulfanCalcineurin inhibitorCanis familiarisCategoriesCell TransplantationCellsChimerismClinicClinical Trials DesignComorbidityComorbidity IndexCyclophosphamideCyclosporineCyclosporinsData AnalysesDecitabineDiseaseDisease remissionDonor Lymphocyte InfusionDoseDysmyelopoietic SyndromesEffectivenessEngraftmentFutureGraft RejectionGraft-Versus-Tumor InductionGrantHealth BenefitHematologic NeoplasmsHematological DiseaseHematopoieticImmuneImmunosuppressionImmunosuppressive AgentsInfectionInfusion proceduresMalignant - descriptorMalignant NeoplasmsMorbidity - disease rateMyeloproliferative diseaseNatural Killer CellsOutcomePatientsPentostatinPharmaceutical PreparationsPhase II Clinical TrialsPhase III Clinical TrialsPrincipal InvestigatorProtocols documentationPublic HealthRandomizedRandomized Controlled Clinical TrialsRecoveryRecurrent diseaseRelapseReproducibilityRiskSeveritiesSirolimusStem cellsSurvival RateTacrolimusTranslatingTransplantationTreatment ProtocolsValidationWhole-Body Irradiationbasechronic graft versus host diseaseconditioningcytotoxicethnic minority populationflufludarabinegraft vs host diseasehigh riskimprovedindexingmortalitymycophenolate mofetilnovel strategiesolder patientpre-clinicalprognosticprogramsprospectiveresponsetrial comparingtumor eradication
项目摘要
PROJECT 3: ALLOGENEIC HCT FORHEMATOLOGIC MALIGNANCIES: IMMUNE MANIPULATIONS
We have translated a novel approach at allogeneic hematopoietic cell transplantation (HCT) into the clinic to
treat patients with hematologic malignancies. The approach uses 2 Gy total body irradiation (TBI) with or
without fludarabine (Flu;90 mg/m2) before and immunosuppression with mycophenolate mofetil and
cyclosporine (CSP), after HCT for control of both engraftment and graft-versus-host disease (GVHD). With
this approach, the burden of tumor eradication has been shifted from the conventional high-dose cytotoxic
conditioning to the HCT donors' immune cells (graft-versus-tumor [GVT] effect). Impressive antitumor
responses have been seen among almost all of the disease categories studied. However, relapse of disease
continues to be a major contributor to poor outcomes in high risk patients. The tempo of donor natural killer
(NK) cell recovery after HCT appeared correlated with relapse risk. This finding has influenced the design of
trials in Specific Aim 1 proposing donor NK cell infusions to reduce relapse. Encouraged by results inHLA-
matched related and unrelated HCT, we have expanded the donor pool to include HLA-haploidentical
donors. This, in combination with NK cell infusions, should provide for GVT effects. Specific Aim 2 addresses
the issue of nonrelapse mortality (NRM). Retrospective findings of increased NRM in patients given Flu are
being addressed in a phase III trial to determine whether Flu is needed in addition to 2 Gy TBI to condition
heavily pretreated patients. GVHD and its extended treatment with immunosuppressive drugs also caused
NRM. In order to reduce GVHD, tacrolimus has been substituted for CSP in a phase II study, and early
results look promising. For acute myelocytic leukemias, outcomes in elderly patients and those with
comorbidities were not different from concurrently transplanted younger patients given myeloablative
conditioning regimens. Based on these findings, we have initiated a phase III study comparing myeloablative
and nonmyeloablative conditioning in younger patients with myeloid malignancies (Specific Aim 3). During
the last grant period, we assessed the impact of comorbidities on survival and cure. After initially using the
Charlson Co-morbidity Index, we developed a hematopoietic cell transplantation-specific index (HCT-Cl),
which seemed to have higher discriminative capacity. In order to validate the HCT-Cl, we propose to address
multi-center issues, as well as inter-rater reproducibility in future studies (Specific Aim 4). The public health
benefits of this Project are that patients with various malignant blood disorders who otherwise would have
been excluded because of age and comorbidities have benefited from treatment by allogeneic HCT. In
addition, the use of HLA-haploidentical donors will extend the option of HCT to a greater number of patients,
including ethnic minorities.
项目3:血液系统恶性肿瘤的同种异体HCT:免疫操作
我们已经将异基因造血细胞移植(HCT)的新方法转化为临床,
治疗恶性血液病患者。该方法使用2戈伊全身照射(TBI),
之前未使用氟达拉滨(Flu;90 mg/m2),并使用吗替麦考酚酯进行免疫抑制,
环孢菌素(CSP),在HCT后用于控制植入和移植物抗宿主病(GVHD)。与
这种方法,肿瘤根除的负担已经从传统的高剂量细胞毒性转移到
调节HCT供体的免疫细胞(移植物抗肿瘤[GVT]效应)。抗肿瘤效果显著
几乎在所有研究的疾病类别中都看到了反应。然而,疾病复发
仍然是高风险患者不良结局的主要原因。捐赠者自然杀手的克里思
(NK)HCT后的细胞恢复似乎与复发风险相关。这一发现影响了
具体目标1中的试验提出供体NK细胞输注以减少复发。受HLA结果的鼓舞-
匹配的相关和无关的HCT,我们扩大了供体库,包括HLA-半相合
捐助者。这与NK细胞输注相结合,应该提供GVT效应。具体目标2地址
非复发死亡率(NRM)。流感患者NRM增加的回顾性结果如下
在III期临床试验中,确定除了2戈伊TBI外,是否还需要流感来治疗
重度预治疗患者。GVHD及其免疫抑制药物的延长治疗也引起了
NRM。为了减少GVHD,他克莫司已在II期研究中取代CSP,并且早期
结果看来很有希望。对于急性髓细胞白血病,老年患者和
合并症与同时接受清髓性移植的年轻患者没有区别
调理方案。基于这些发现,我们启动了一项III期研究,
和非清髓性预处理在年轻骨髓恶性肿瘤患者中的应用(具体目标3)。期间
在最后一个资助期,我们评估了合并症对生存和治愈的影响。在最初使用
Charlson共病指数,我们开发了造血细胞移植特异性指数(HCT-Cl),
这似乎具有更高的辨别能力。为了验证HCT-Cl,我们建议解决
多中心问题,以及未来研究中的评价者间重现性(具体目标4)。公共卫生
该项目的好处是,患有各种恶性血液病的患者,
由于年龄和合并症而被排除,从同种异体HCT治疗中获益。在
此外,HLA-半相合供体的使用将使HCT的选择扩展到更多的患者,
包括少数族裔。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRENDA MARIE SANDMAIER其他文献
BRENDA MARIE SANDMAIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRENDA MARIE SANDMAIER', 18)}}的其他基金
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
9301083 - 财政年份:2016
- 资助金额:
$ 24.04万 - 项目类别:
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
9327864 - 财政年份:2016
- 资助金额:
$ 24.04万 - 项目类别:
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
8842434 - 财政年份:2014
- 资助金额:
$ 24.04万 - 项目类别:
Alpha Radioimmunotherapy for Lymphoma Treatment
淋巴瘤治疗的阿尔法放射免疫疗法
- 批准号:
8782611 - 财政年份:2013
- 资助金额:
$ 24.04万 - 项目类别:
Alpha Radioimmunotherapy for Lymphoma Treatment
淋巴瘤治疗的阿尔法放射免疫疗法
- 批准号:
8601179 - 财政年份:2013
- 资助金额:
$ 24.04万 - 项目类别:
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations
同种异体 HCT 治疗血液系统恶性肿瘤:免疫操作
- 批准号:
8240005 - 财政年份:2011
- 资助金额:
$ 24.04万 - 项目类别:
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD
DLA 单倍体狗的非清髓性同种异体移植:移植和 GVHD
- 批准号:
7478449 - 财政年份:2007
- 资助金额:
$ 24.04万 - 项目类别:
Core--Protocol Management and Coordination of Multi-center Trials
核心--多中心试验的方案管理和协调
- 批准号:
7478453 - 财政年份:2007
- 资助金额:
$ 24.04万 - 项目类别:
Core--Protocol Management and Coordination of Multi-center Trials
核心--多中心试验的方案管理和协调
- 批准号:
7304871 - 财政年份:2006
- 资助金额:
$ 24.04万 - 项目类别:
相似海外基金
A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease
一种治疗急性移植物抗宿主病的新型小分子疗法
- 批准号:
10759657 - 财政年份:2023
- 资助金额:
$ 24.04万 - 项目类别:
Investigation of the association between acute graft-versus-host disease and renal impairment.
急性移植物抗宿主病与肾功能损害之间关系的调查。
- 批准号:
23K19558 - 财政年份:2023
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Impact of gut mycobiome on acute graft-versus-host disease
肠道真菌组对急性移植物抗宿主病的影响
- 批准号:
20K08748 - 财政年份:2020
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Harnessing the single-cell biology and biomarker involving in the therapeutic response of patients with severe acute graft-versus-host disease undergoing mesenchymal stem cell transfusion
利用单细胞生物学和生物标志物参与接受间充质干细胞输注的严重急性移植物抗宿主病患者的治疗反应
- 批准号:
19K16605 - 财政年份:2019
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effectiveness of dimethyl fumarate for acute graft-versus-host disease
富马酸二甲酯治疗急性移植物抗宿主病的有效性
- 批准号:
19K24001 - 财政年份:2019
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Role of T cells and the Intestinal Microbiota in the Pathogenesis of Acute Graft- versus- Host Disease
T 细胞和肠道微生物群在急性移植物抗宿主病发病机制中的作用
- 批准号:
9754362 - 财政年份:2019
- 资助金额:
$ 24.04万 - 项目类别:
Frequency analysis of graft-versus-host reactive T cell clones in human acute graft-versus-host disease tissues
人急性移植物抗宿主病组织中移植物抗宿主反应性T细胞克隆的频率分析
- 批准号:
18K08321 - 财政年份:2018
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Prevention of acute Graft-versus-Host disease after allogeneic stem cell transplantation by molecular targeting of anti-apoptotic proteins in activated donor T-cells (A08*)
通过分子靶向活化供体 T 细胞中的抗凋亡蛋白来预防同种异体干细胞移植后的急性移植物抗宿主病 (A08*)
- 批准号:
278130007 - 财政年份:2015
- 资助金额:
$ 24.04万 - 项目类别:
Collaborative Research Centres
Pathological analysis of acute graft-versus-host disease and development of molecular targeted therapy for acute GVHD
急性移植物抗宿主病的病理分析及急性GVHD分子靶向治疗的进展
- 批准号:
15K09657 - 财政年份:2015
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Altered Exosomal miRNA expression of late onset acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
异基因造血干细胞移植中迟发型急性移植物抗宿主病外泌体 miRNA 表达的改变。
- 批准号:
26860373 - 财政年份:2014
- 资助金额:
$ 24.04万 - 项目类别:
Grant-in-Aid for Young Scientists (B)